LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES

被引：0
|
作者：
Kaura, S. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Augmentium Pharma Consulting, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1727
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A508 / A509
页数：2
相关论文
共 50 条
  • [1] LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES
    Dranitsaris, G.
    Kaura, S.
    HAEMATOLOGICA, 2012, 97 : 620 - 620
  • [2] LENALIDOMIDE VERSUS BORTEZOMIB FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A NUMBER NEEDED TO TREAT (NNT) ANALYSIS
    Kaura, S.
    Dranitsaris, G.
    VALUE IN HEALTH, 2012, 15 (07) : A654 - A654
  • [3] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [4] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [5] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
  • [6] Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Gkotzamanidou, Maria
    Iakovaki, Marina
    Roussou, Maria
    Efstathiou, Eleni
    Terpos, Evangelos
    BLOOD, 2009, 114 (22) : 395 - 396
  • [7] Number needed to treat (NNT) as a measure of drug benefit: Lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (MM).
    Kaura, Satyin
    Dranitsaris, George
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis
    Leonardo Javier Arcuri
    Andre Dias Americo
    Annals of Hematology, 2021, 100 : 725 - 734
  • [9] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
  • [10] Prolonged treatment with lenalidomide in relapsed and refractory multiple myeloma
    Franco C.A.
    Palomera L.
    Arredondo J.J.R.
    Sánchez J.M.
    Advances in Therapy, 2011, 28 (Suppl 8) : 14 - 19
12345